SWEDISH ORPHAN BIOVIT.SK1/ SE0000872095 /
16/10/2024 16:36:17 | Chg. +0.060 | Volume | Bid16:36:17 | Ask16:36:17 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
25.900EUR | +0.23% | - Turnover: - |
25.900Bid Size: - | 26.000Ask Size: - | 9.24 bill.EUR | - | - |
GlobeNewswire
24/05
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
07/09/2021
Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...
GlobeNewswire
22/12/2020
FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
GlobeNewswire
04/05/2016
Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
GlobeNewswire
11/04/2016
COMP recommends that Alprolix® maintains orphan designation for treatment of haemophilia B
GlobeNewswire
24/03/2016
European Commission approves transfer of marketing authorisation for Elocta® to Sobi
GlobeNewswire
26/02/2016
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemo...
GlobeNewswire
26/02/2016
Bo Jesper Hansen to step down as Chairman of Sobi - Håkan Björklund to be nominated as new Chairman ...
GlobeNewswire
23/02/2016
Sobi to initiate clinical development programs in acute gout and Still's disease, and receives US pa...
GlobeNewswire
17/02/2016
Invitation - Presentation of Sobi's fourth quarter and full year results 2015
GlobeNewswire
28/01/2016
Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleedi...
GlobeNewswire
11/01/2016
Sobi(TM) announces commercial launch of Elocta® in first countries in Europe